DARE

Dare Bioscience Inc

0.7734

Oct 09 • 3:59 PM ET +0.0012 (0.16%)

0.7723

Aftermarket • 6:17 PM ET -0.0011 (-0.14%)

Healthcare Biotechnology USA Nano NASD

Oct 08, 9:50 AMDaré Bioscience reports Phase 1 data showing topical Sildenafil Cream has substantially lower systemic exposure, mild adverse events vs oral sildenafil

Peers: ALGS LITS ABVC EVAX NNVC TVRD BOLD GRCE VERU INMB

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	15.21M
Enterprise Value	9.35M
Income	-10.99M
Sales	1.37M
Book/sh	-0.04
Cash/sh	0.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	24
IPO	Apr 10, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	11.10
P/B	-
P/C	1.21
P/FCF	-
EV/EBITDA	-
EV/Sales	6.83
Quick Ratio	0.99
Current Ratio	0.99
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.79
EPS next Y	-0.41
EPS next Q	-0.14
EPS this Y	34.72%
EPS next Y	47.02%
EPS next 5Y	-
EPS past 3/5Y	35.13% 35.73%
Sales past 3/5Y	-53.12% -
EPS Y/Y TTM	-82.83%
Sales Y/Y TTM	-
EPS Q/Q	55.76%
Sales Q/Q	985.82%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	32.59% 10929.41%

Insider Own	12.47%
Insider Trans	0.00%
Inst Own	12.18%
Inst Trans	7.82%
ROA	-62.16%
ROE	-
ROIC	-201.69%
Gross Margin	-128.01%
Oper. Margin	-813.38%
Profit Margin	-804.37%
SMA20	-2.29%
SMA50	-13.50%
SMA200	-53.94%
Trades

Shs Outstand	19.67M
Shs Float	17.22M
Short Float	5.35%
Short Ratio	1.77
Short Interest	0.92M
52W High	3.78 -79.54%
52W Low	0.69 12.09%
Volatility	4.86% 7.87%
ATR (14)	0.07
RSI (14)	42.34
Beta	1.08
Rel Volume	0.13
Avg Volume	519.48K
Volume	70,037

Perf Week	-8.23%
Perf Month	9.69%
Perf Quarter	-63.00%
Perf Half Y	-57.74%
Perf YTD	-59.93%
Perf Year	-65.32%
Perf 3Y	-86.00%
Perf 5Y	-95.92%
Perf 10Y	-99.34%
Recom	1.00
Target Price	8.33
Prev Close	0.77
Price	0.77
Change %	0.16%

Oct-08-26 09:15AM	Dare Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting (GlobeNewswire)
Sep-28-26 10:32AM	Dare Bioscience stock rises after receiving HPV treatment patent (Investing.com)
08:20AM	Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection (GlobeNewswire)
Sep-14-26 08:50AM	Dare Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil (GlobeNewswire)
Sep-11-26 06:55AM	Dare Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand (GlobeNewswire)
08:44AM	Loading…
Aug-31-26 08:44AM	Dare Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth (GlobeNewswire)
Aug-27-26 09:01AM	Dare Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor "Why Now" On-Demand Series (GlobeNewswire)
Aug-26-26 08:45AM	Dare Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society (GlobeNewswire) -8.54%
Aug-25-26 08:55AM	Dare Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment (GlobeNewswire)
Aug-18-26 09:02AM	DARE Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 "50 Over 50: Innovation" List (GlobeNewswire) -5.18%
Aug-17-26 04:34PM	Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ... (GuruFocus.com) -12.88%
Aug-14-26 12:45PM	Dare Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -32.12%
08:30AM	Daré Bioscience, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-13-26 04:01PM	Dare Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances (GlobeNewswire)
Aug-06-26 09:05AM	Dare Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 (GlobeNewswire)
08:34AM	Loading…
Jul-28-26 08:34AM	Dare Bioscience Expands Access Options for DARE to PLAY and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx (GlobeNewswire) -10.23%
Jul-20-26 09:01AM	Dare Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities (GlobeNewswire) -31.63%
Jul-09-26 08:43AM	Dare Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event (GlobeNewswire)
Jul-01-26 08:55AM	Dare Bioscience Announces Flora Sync LF5 Is Now Available Through Its Direct-to-Consumer Platform (GlobeNewswire)
Jun-25-26 09:05AM	Dare Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5 in Virtual Investor "What This Means" Segment (GlobeNewswire)
Jun-18-26 09:20AM	Dare Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 (GlobeNewswire)
Jun-04-26 08:00AM	Dare Bioscience Announces the Upcoming Launch of Flora Sync LF5 Vaginal Probiotic Capsules (GlobeNewswire) +6.34%
May-26-26 08:00AM	Dare Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer (GlobeNewswire)
May-18-26 08:00AM	Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies (GlobeNewswire)
May-15-26 01:03AM	Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ... (GuruFocus.com) -24.13%
May-14-26 04:01PM	Dare Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 08:00AM	Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive (GlobeNewswire)
May-07-26 08:00AM	Dare Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026 (GlobeNewswire) -7.91%
Mar-26-26 04:01PM	Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.86%
Mar-25-26 09:22AM	Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
08:00AM	Loading…
Mar-23-26 08:00AM	On National Viagra Day, Women Finally Claim Their Turn: (GlobeNewswire)
Mar-20-26 08:00AM	Dare Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 (GlobeNewswire)
Mar-16-26 08:00AM	Dare Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth (GlobeNewswire)
Mar-12-26 08:00AM	Dare Bioscience Participates in Virtual Investor "What This Means" Segment (GlobeNewswire)
Mar-09-26 08:25AM	Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-02-26 08:20AM	uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.29%
Feb-23-26 08:00AM	Dare Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer (GlobeNewswire)
Feb-11-26 08:00AM	Telehealth Now Available for DARE to PLAY Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women (GlobeNewswire)
Dec-10-25 08:00AM	DARE to PLAY Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility (GlobeNewswire) +6.99%
Dec-01-25 08:00AM	Dare Bioscience Announces Return of Rights to Ovaprene; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization (GlobeNewswire) -9.24%
Nov-24-25 08:00AM	Dare Bioscience Receives $3.6 Million in Additional Grant Funding (GlobeNewswire) +6.55%
Nov-14-25 12:02AM	Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Nov-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Dare Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-25 05:30PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:37AM	Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result (GuruFocus.com)
Nov-11-25 08:00AM	Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health (GlobeNewswire) +6.59%
Nov-10-25 08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-06-25 06:25PM	Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Dare Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 (GlobeNewswire)
Nov-05-25 05:10PM	Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 08:55AM	AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.73%
Nov-03-25 08:00AM	Dare Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment (GlobeNewswire)
Oct-06-25 08:00AM	Dare Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders (GlobeNewswire)
Sep-24-25 08:00AM	Dare Bioscience to Receive up to $499,000 to Support Preeclampsia Research (GlobeNewswire)
Aug-15-25 03:23AM	Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) +6.28%
Aug-14-25 05:15PM	Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Dare Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-13-25 08:15AM	Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-12-25 05:15PM	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -9.73%
08:00AM	Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 (GlobeNewswire)
08:00AM	Dare Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 (GlobeNewswire)
Aug-06-25 08:15AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.83%
Jul-29-25 08:00AM	Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil Cream (GlobeNewswire)
08:00AM	Dare Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil Cream (GlobeNewswire)
Jul-21-25 01:47PM	UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar (GlobeNewswire) +6.35%
01:47PM	UPDATE - Dare Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar (GlobeNewswire)
08:00AM	Daré Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar (GlobeNewswire)
08:00AM	Dare Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar (GlobeNewswire)
Jul-14-25 08:00AM	Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive (GlobeNewswire) +22.86%
Jul-11-25 08:00AM	Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders (GlobeNewswire) +5.23%
08:00AM	Dare Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders (GlobeNewswire)
Jun-12-25 05:00PM	Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
05:00PM	Dare Bioscience Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jun-06-25 09:40AM	Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-04-25 08:00AM	Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Darés DARE to PLAY Sildenafil Cream (GlobeNewswire)
08:00AM	Dare Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Dare's DARE to PLAY Sildenafil Cream (GlobeNewswire)
May-14-25 12:53PM	Q1 2025 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents)
03:14AM	Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ... (GuruFocus.com)
May-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update (GlobeNewswire)
04:01PM	Dare Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update (GlobeNewswire)
May-12-25 05:25PM	Acadia Healthcare (ACHC) Beats Q1 Earnings Estimates (Zacks)
May-08-25 06:10PM	Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 08:00AM	Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 (GlobeNewswire)
08:00AM	Dare Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 (GlobeNewswire)
Apr-23-25 08:00AM	Dare Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation (GlobeNewswire)
08:00AM	Dar Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation (GlobeNewswire)
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Apr-07-25 08:00AM	Dar Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year (GlobeNewswire)
Apr-01-25 09:56AM	Q4 2024 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Mar-31-25 10:14PM	Dare Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript (Seeking Alpha)
05:15PM	Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Dare Bioscience Reports Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
04:01PM	Dar Bioscience Reports Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
Mar-24-25 08:00AM	Dare Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 (GlobeNewswire)
08:00AM	Dar Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 (GlobeNewswire)

Dare Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

CEOMs. Sabrina Martucci Johnson

Chief Accounting OfficerMs. MarDee J. Haring-Layton

Vice President of OperationsMr. Mark Walters

Chief Scientific OfficerDr. David Friend Ph.D.

Vice President of Corporate Affairs & DevelopmentJennifer Kiang

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DARE

Dare Bioscience Inc

Upgrade your Finviz experience